Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

Nature Communications

Volumn 7, Issue , 2016, Pages

  McGuire, Andrew T ^a   Gray, Matthew D ^a   Dosenovic, Pia ^b   Gitlin, Alexander D ^b   Freund, Natalia T ^b   Petersen, John ^a   Correnti, Colin ^a   Johnsen, William ^a   Kegel, Robert ^a   Stuart, Andrew B ^a   Glenn, Jolene ^a   Seaman, Michael S ^c   Schief, William R ^d,e   Strong, Roland K ^a   Nussenzweig, Michel C ^b,f   Stamatatos, Leonidas ^a,g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Laboratory of Molecular Immunology   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

426C PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; B LYMPHOCYTE RECEPTOR; GLYCOPROTEIN GP 140; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GL12A21; MONOCLONAL ANTIBODY GL3BNC60; MONOCLONAL ANTIBODY GLNIH45 46; MONOCLONAL ANTIBODY GLVRC CH31; MONOCLONAL ANTIBODY GLVRC PG04; MONOCLONAL ANTIBODY GLVRC PG19; MONOCLONAL ANTIBODY GLVRC PG20; MONOCLONAL ANTIBODY GLVRC01; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ENVELOPE PROTEIN;

ANTIBODY; CELLS AND CELL COMPONENTS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LIGHT; OPTIMIZATION; PHENOTYPE; RODENT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; FEMALE; GERMLINE MUTATION; HEAVY CHAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; LIGHT CHAIN; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; VIRUS NEUTRALIZATION; ANIMAL; B LYMPHOCYTE; GENE TARGETING; GENETICS; IMMUNIZATION; IMMUNOLOGY; TRANSGENIC MOUSE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE KNOCK-IN TECHNIQUES; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MICE, TRANSGENIC; PRECURSOR CELLS, B-LYMPHOID; RECEPTORS, ANTIGEN, B-CELL;

EID: 84959378678     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10618     Document Type: Article

References (48)

1. Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571-576 (2015
2. West, Jr A. P., et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633-648 (2014
3. Zhou, T., et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161, 1280-1292 (2015
4. Rudicell, R. S., et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669-12682 (2014
5. Shingai, M., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061-2074 (2014
6. Saunders, K. O., et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-Term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895-5903 (2015
7. Saunders, K. O., et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simianhuman immunodeficiency virus infection. J. Virol. 89, 8334-8345 (2015
8. Deal, C. E. & Balazs, A. B. Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr. Opin. HIV AIDS 10, 190-197 (2015
9. Gruell, H., et al. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J. Virol. 87, 8535-8544 (2013
10. McCoy, L. E., et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209, 1091-1103 (2012
11. Hoot, S., et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 9, e1003106 (2013
12. Jardine, J., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-716 (2013
13. McGuire, A. T., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210, 655-663 (2013
14. Diskin, R., et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289-1293 (2011
15. Zhou, T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010
16. Zhou, T., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245-258 (2013
17. DeKosky, B. J., et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86-91 (2015
18. Dosenovic, P., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161, 1505-1515 (2015
19. Finton, K. A., et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 9, e1003639 (2013
20. Chen, Y., et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 191, 1260-1275 (2013
21. Doyle-Cooper, C., et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 191, 3186-3191 (2013
22. Nemazee, D. A. & Burki, K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337, 562-566 (1989
23. Goodnow, C. C., et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334, 676-682 (1988
24. Scheid, J. F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011
25. Wu, X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011
26. Wu, X., et al. Maturation and diversity of the VRC01-Antibody lineage over 15 years of chronic HIV-1 infection. Cell 161, 470-485 (2015
27. Georgiev, I. S., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013
28. McGuire, A. T., et al. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346, 1380-1383 (2014
29. West, Jr. A. P., Diskin, R., Nussenzweig, M. C. & Bjorkman, P. J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl Acad. Sci. USA 109, E2083-E2090 (2012
30. Tran, K., et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl Acad. Sci. USA 111, E738-E747 (2014
31. Cooke, M. P., et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J. Exp. Med. 179, 425-438 (1994
32. Batista, F. D. & Neuberger, M. S. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8, 751-759 (1998
33. Sabouri, Z., et al. Redemption of autoantibodies on anergic B cells by variableregion glycosylation and mutation away from self-reactivity. Proc. Natl Acad. Sci. USA 111, E2567-E2575 (2014
34. Hofmeyer, T., et al. Arranged sevenfold: structural insights into the C-Terminal oligomerization domain of human C4b-binding protein. J. Mol. Biol. 425, 1302-1317 (2013
35. Kanekiyo, M., et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090-1100 (2015
36. Jardine, J. G., et al. HIV-1 vaccines. Priming a broadly neutralizing antibody response to HIV-1 using a germline-Targeting immunogen. Science 349, 156-161 (2015
37. Xiao, X., Chen, W., Feng, Y. & Dimitrov, D. S. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 1, 802-817 (2009
38. Klein, F., et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013
39. Doria-Rose, N. A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014
40. Liao, H. X., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013
41. Williams, W. B., et al. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 349, aab1253 (2015
42. Liu, M., et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89, 784-798 (2015
43. Verkoczy, L., et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-Associated autoreactivity limits T-dependent responses. J. Immunol. 191, 2538-2550 (2013
44. McGuire, A. T., Glenn, J. A., Lippy, A. & Stamatatos, L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 88, 2645-2657 (2013
45. Pelanda, R., et al. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 7, 765-775 (1997
46. Shih, T. A., Roederer, M. & Nussenzweig, M. C. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3, 399-406 (2002
47. Tiller, T., Busse, C. E. & Wardemann, H. Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350, 183-193 (2009
48. Li, M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005